Aktienanalyse zu C4 Therapeutics Inc (CCCC)CCCCC4 Therapeutics Inc

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

C4 Therapeutics Inc is a good buy right now, given its current price of $3.21 and a significant upside potential indicated by JPMorgan's $10 price target. Additionally, the company has shown a 66.32% year-to-date change and a 7.72% increase over the past five days, suggesting positive momentum. However, the main risk is its ongoing net losses, with a reported net loss of $23.63 million in Q2 2026.